INmune Bio (NASDAQ:INMB) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

INmune Bio (NASDAQ:INMB) released its quarterly earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11), Zacks reports. INmune Bio had a negative return on equity of 121.57% and a negative net margin of 26,333.59%. During the same quarter last year, the company posted ($0.48) EPS.

INmune Bio Trading Up 3.2 %

NASDAQ:INMB traded up $0.19 during mid-day trading on Friday, hitting $6.04. The stock had a trading volume of 225,027 shares, compared to its average volume of 228,751. INmune Bio has a 52 week low of $4.78 and a 52 week high of $14.74. The stock has a market capitalization of $119.35 million, a price-to-earnings ratio of -2.77 and a beta of 1.84. The company has a 50 day simple moving average of $5.64 and a 200-day simple moving average of $7.78.

Insider Buying and Selling at INmune Bio

In other INmune Bio news, CFO David J. Moss purchased 7,690 shares of INmune Bio stock in a transaction on Thursday, September 12th. The stock was bought at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the transaction, the chief financial officer now owns 1,275,869 shares of the company’s stock, valued at $8,140,044.22. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other INmune Bio news, CFO David J. Moss bought 7,690 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, with a total value of $49,062.20. Following the completion of the purchase, the chief financial officer now directly owns 1,275,869 shares in the company, valued at approximately $8,140,044.22. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Raymond Joseph Tesi bought 15,380 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $6.38 per share, for a total transaction of $98,124.40. Following the completion of the transaction, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 33,070 shares of company stock worth $200,087. 35.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on INMB. Raymond James assumed coverage on INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 price target for the company. Alliance Global Partners assumed coverage on shares of INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Scotiabank started coverage on INmune Bio in a report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 target price for the company.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.